Results 181 to 190 of about 2,136,839 (361)

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Learning under uncertainty-Conservation of populations and persistence of dynamic resources through adaptive switching feedback controllers. [PDF]

PLoS One
Smith P, Guiver C.
europepmc   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Designing Magnetic Topological Insulator Trilayers for Highly Efficient Spin-Orbit Torque Switching. [PDF]

Nano Lett
Zhou LJ, Zhuo D, Tay H, Yan ZJ, Xiao P, Liu X, Zhang B, Chang CZ.   +7 more
europepmc   +1 more source

Customer perceived value, satisfaction, and loyalty: The role of switching costs

, 2004
Zhilin Yang, R. Peterson
semanticscholar   +1 more source

Commentary: What switch, to switch or not to switch: That is the question! [PDF]

JTCVS Techniques, 2020
openaire   +2 more sources

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Testing the null hypothesis of no regime switching with an application to GDP growth rates [PDF]

This paper presents tests for the null hypothesis of no regime switching in Hamilton's (1989) regime switching model. The test procedures exploit similarities between regime switching models, autoregressions with measurement errors, and finite mixture ...
Marmer, Vadim
core  

Effects of Histamine H₃ Receptor Antagonist/Inverse Agonist Pitolisant on Temporal Prediction, Spatial Switching, and Spontaneous Locomotion in Mice. [PDF]

Neuropsychopharmacol Rep
Kaneko S, Hayashi K, Yamada K, Toda K.
europepmc   +1 more source

switching costs

, 2008
Switching costs arise when transactions, learning, or pecuniary costs are incurred by a user who changes suppliers (including for ‘follow-on’ or ‘aftermarket’ products such as refills and repairs). The ex post market power that switching costs give suppliers need not create inefficiencies, and early ‘bargain’ prices can compensate consumers for later ...
openaire   +1 more source